Γ
Content Highlights || Full Agenda
Spotlight Talk

9:20 AM

-

9:30 AM

AIxBIO

Designing Enzymes Without Compromise. Powered by Intelligent Architecture™

Biology will be the center of the next industrial revolution, representing a $4 trillion economic opportunity. Yet, this value remains overwhelmingly unrealised for one fundamental reason: nature never intended to power industrial manufacturing. Biology was optimized for survival, not for the high-efficiency processes required to transform the global economy. For too long, the industry has relied on incremental improvements, essentially duct-taping enzymes and calling them industrial. At Biomatter, we believe that complete freedom to design any enzyme is the only way to realize the full potential of biomanufacturing. By combining Generative AI with rigorous physics engines, our Intelligent Architecture™ platform allows us to step outside the bounds of natural selection and build enzymes from the bottom up. We are turning the "previously impossible" into routine. From liberating enzymes of their cofactor dependencies for mRNA raw materials to designing lactases that reject the trade-off between lactose removal and high GOS fiber formation, we are proving that biology’s limits are negotiable. Join us to see how we are building the enzymes nature couldn't.

Spotlight Talk

9:20 AM

-

9:30 AM

AIxBIO

Designing Enzymes Without Compromise. Powered by Intelligent Architecture™

Biology will be the center of the next industrial revolution, representing a $4 trillion economic opportunity. Yet, this value remains overwhelmingly unrealised for one fundamental reason: nature never intended to power industrial manufacturing. Biology was optimized for survival, not for the high-efficiency processes required to transform the global economy. For too long, the industry has relied on incremental improvements, essentially duct-taping enzymes and calling them industrial. At Biomatter, we believe that complete freedom to design any enzyme is the only way to realize the full potential of biomanufacturing. By combining Generative AI with rigorous physics engines, our Intelligent Architecture™ platform allows us to step outside the bounds of natural selection and build enzymes from the bottom up. We are turning the "previously impossible" into routine. From liberating enzymes of their cofactor dependencies for mRNA raw materials to designing lactases that reject the trade-off between lactose removal and high GOS fiber formation, we are proving that biology’s limits are negotiable. Join us to see how we are building the enzymes nature couldn't.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: